Literature DB >> 19465221

Ranking antidepressants.

John P A Ioannidis.   

Abstract

Mesh：

Substances：

Year:  2009        PMID： 19465221     DOI： 10.1016/S0140-6736(09)60974-0

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  9 in total

Review 1.  How should primary care doctors select which antidepressants to administer?

Authors:  Gerald Gartlehner; Kylie Thaler; Seth Hill; Richard A Hansen
Journal:  Curr Psychiatry Rep       Date:  2012-08       Impact factor: 5.285

2.  The Mass Production of Redundant, Misleading, and Conflicted Systematic Reviews and Meta-analyses.

Authors:  John P A Ioannidis
Journal:  Milbank Q       Date:  2016-09       Impact factor: 4.911

Review 3.  Is escitalopram really relevantly superior to citalopram in treatment of major depressive disorder? A meta-analysis of head-to-head randomized trials.

Authors:  Vladimir Trkulja
Journal:  Croat Med J       Date:  2010-02       Impact factor: 1.351

4.  Network meta-analysis-highly attractive but more methodological research is needed.

Authors:  Tianjing Li; Milo A Puhan; Swaroop S Vedula; Sonal Singh; Kay Dickersin
Journal:  BMC Med       Date:  2011-06-27       Impact factor: 8.775

5.  The effects of excluding treatments from network meta-analyses: survey.

Authors:  Edward J Mills; Steve Kanters; Kristian Thorlund; Anna Chaimani; Areti-Angeliki Veroniki; John P A Ioannidis
Journal:  BMJ       Date:  2013-09-05

6.  Efficacy of new generation antidepressants: differences seem illusory.

Authors:  A C Del Re; Glen I Spielmans; Christoph Flückiger; Bruce E Wampold
Journal:  PLoS One       Date:  2013-06-03       Impact factor: 3.240

7.  Ranking treatments in frequentist network meta-analysis works without resampling methods.

Authors:  Gerta Rücker; Guido Schwarzer
Journal:  BMC Med Res Methodol       Date:  2015-07-31       Impact factor: 4.615

8.  Which placebo to cure depression? A thought-provoking network meta-analysis.

Authors:  Florian Naudet; Bruno Millet; Philippe Charlier; Jean Michel Reymann; Anne Solène Maria; Bruno Falissard
Journal:  BMC Med       Date:  2013-10-25       Impact factor: 8.775

9.  Can we well assess the relative efficacy and tolerability of a new drug versus others at the time of marketing authorization using mixed treatment comparisons? A detailed illustration with escitalopram.

Authors:  Pierre-Michel Llorca; Christophe Lançon; Mélanie Brignone; Caroline Painchault; Benoit Rive; Mondher Toumi; Clément François
Journal:  J Mark Access Health Policy       Date:  2015-09-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.